HT treatment with estrogens alone or in combination with progestogens was associated with a small to moderate improvement in sexual function , particularly in pain , when used in women with menopausal symptoms or in early postmenopause ( within five years of amenorrhoea ) , but not in unselected postmenopausal women .
The current evidence does not suggest an important effect of tibolone or of SERMs alone or combined with estrogens on sexual function .
BACKGROUND The perimenopausal and postmenopausal periods are associated with many symptoms , including sexual complaints .
OBJECTIVES To assess the effect of hormone therapy ( HT ) on  sexual function in perimenopausal and postmenopausal women .
Vaginal estrogen therapy and overactive bladder symptoms in postmenopausal patients after a tension-free vaginal tape procedure: a randomized clinical trial
Objective : To evaluate whether the frequency of overactive bladder ( OAB ) symptoms increases in menopause patients after a tension-free vaginal tape ( TVT ) procedure  , and to determine if topical estrogen therapy can help prevent these symptoms . Design : After undergoing a preoperative assessment , enrolled patients were r and omly allocated to receive TVT plus postoperative vaginal estrogen therapy ( ET group ) or TVT without adjunctive medical treatment ( No ET group ) . The pre- and postoperative assessment s included : acquisition of a urogynecologic history with st and ardized questions regarding urinary function ( including a 10- grade visual analogue scale score ) , urogynecologic clinical examination , and urodynamic assessment . Follow-up assessment s were performed at 1 , 3 , and 6 months after surgery . Results : Fifty-six of 59 patients were evaluable ; 28 received topic vaginal estrogen after surgery ( ET group ) and 28 did not receive adjunctive medical treatment ( No ET group ) . The overall OAB syndrome rate in menopause patients ( No ET group ) was 7 % ( 2 of 28 patients ) at baseline and 32 % ( 9 of 28 patients ) 6 months after surgery ( P = 0.04 ) . At the 6-month follow-up assessment , the incidence of urinary urgency was 4 % ( 1 of 28 patients ) and 29 % ( 8 of 28 patients ) in the ET and No ET groups , respectively ( P = 0.01 ) . Differences in frequency and nocturia were not statistically significant . Analysis of the visual analogue scale scores revealed that at the 6-month follow-up assessment , urgency significantly improved in the ET group compared with the No ET group ( 0.23 ± 1.0 vs 2.30 ± 3.7 , respectively ; P = 0.02 ) . Conclusions : The TVT procedure seems to increase the frequency of OAB syndrome  in menopause patients .  Vaginal estriol therapy significantly reduces symptoms of urinary urgency , has a high rate of patient satisfaction , and can be used to treat postmenopausal women for at least 6 months after a TVT procedure
HT treatment with estrogens alone or in combination with progestogens was associated with a small to moderate improvement in sexual function , particularly in pain , when used in women with menopausal symptoms or in early postmenopause ( within five years of amenorrhoea ) , but not in unselected postmenopausal women .
The current evidence does not suggest an important effect of tibolone or of SERMs alone or combined with estrogens on sexual function .
BACKGROUND The perimenopausal and postmenopausal periods are associated with many symptoms , including sexual complaints .
OBJECTIVES To assess the effect of hormone therapy ( HT ) on  sexual function in perimenopausal and postmenopausal women .